Chinese biotech startups Belief Biomed is one of the few gene therapy players with in-house manufacturing capabilities, and Regor is able to deliver one preclinical candidate in 10 months with its rCARD platform.
BeiGene aims 10 new molecules in clinic each year from 2024, Zai Lab targets 15+ marketed products across 35+ indications by 2025, RemeGen serves as Seagen’s ADC partner in China, and Legend gets ready for BCMA CAR-T launch.
Sinovac’s revenue soared 161 times thanks to its COVID-19 vaccine and CanSino is looking into an inhalable vaccine as booster, executives revealed at the 40th Annual J.P. Morgan Health Care Conference on Monday.
This year, 33 mainland Chinese companies, ranging from drugmakers to CROs, will be addressing to investors and analysts at biotech's biggest annual conference from Jan. 10 to Jan. 13, up from 22 last year.
SIR-Spheres Y-90 resin microspheres have been used in selective internal radiation therapy in the U.S. for almost two decades. Now they have come to China to treat patients with unresectable liver cancer.
BeiGene is now looking to support local startups to explore beyond oncology and autoimmune diseases. Its new innovation center in Guangzhou is set to foster a biotech ecosystem that it believes is long overdue.
After launching the first CAR-T therapy on China market, Richard Wang wants to stay on the R&D frontier to push for safer, more affordable and efficacious cell therapies for more patients with the iPSC-CAR-NK technology. To succeed, emphasizing innovation and CMC early on is key, he told PharmaDJ.